NASDAQ · Biotechnology · USD
Oncolytics Biotech Inc. (ONCY) Stock Analysis
Oncolytics Biotech Inc. (ONCY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ONCY Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.50
- Previous Close
- $0.50
- Day's Range
- 0.49–0.52
- 52-Week Range
- 0.44–1.32
- Volume
- 771.63K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.16
Valuation
- Market Cap
- $67.06M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.35
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$28.76M
- Shares Outstanding
- 131.12M
- 1-Year Return
- −53.93%
Dividend and dates
- Earnings Date
- November 16, 2026estimated
- Avg Volume
- 1.06M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ONCY closed at $0.51, −53.93% over 1 year.
Oncolytics Biotech Inc. (ONCY) has a market capitalization of $67.06M.
In fiscal 2025, ONCY reported revenue of $0.00.
ONCY Stock Return by Calendar Year
Oncolytics Biotech Inc. (ONCY) 10-year return: what $10,000 became
- 1 year
- $10,000 $4,607
- −53.93%
- 5 years
- $10,000 $2,223
- −77.77%
- 10 years
- $10,000 $2,153
- −78.47%
If you had invested $10,000 in Oncolytics Biotech Inc. (ONCY) 10 years ago, at the close on October 21, 2016, it would have been worth $2,153 at the close on October 21, 2026: −78.47% in total, −14.24% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −41.22% |
| 2025 | −4.40% |
| 2024 | −32.59% |
| 2023 | −17.18% |
| 2022 | +17.27% |
| 2021 | −41.60% |
| 2020 | −50.00% |
| 2019 | +162.98% |
| 2018 | −66.57% |
| 2017 | +171.43% |
| 2016 (partial year) | −32.26% |
As of October 21, 2026.
ONCY Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$28.76M | — |
| 2024 | $0.00 | −$22.79M | — |
| 2023 | $0.00 | −$20.92M | — |
| 2022 | $0.00 | −$18.30M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$28.73M | −$28.76M | — |
| 2024 | $0.00 | — | −$25.54M | −$22.79M | — |
| 2023 | $0.00 | — | −$25.47M | −$20.92M | — |
| 2022 | $0.00 | — | −$19.84M | −$18.30M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
YahooOncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology
BenzingaOncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
YahooOncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter
BenzingaOncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
YahooOncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044
Benzinga
All 16 articles ↓Show fewer ↑
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
YahooOncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences
BenzingaOncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
YahooOncolytics Biotech's All Planned Facilities For Part A Of REO 033 Trial Activated, Multiple Participants Admitted
BenzingaOncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
YahooOncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period
BenzingaHC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
BenzingaWhy Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials
YahooOncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
YahooOncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B